PARP inhibitor
PARP inhibitor is a pharmaceutical drug with 8 clinical trials. Currently 4 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
5
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
1 of 1 finished
0.0%
0 ended early
4
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
Clinical Trials (8)
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
PD1 and PARP for Maintenance Therapy in NSLLC
Pancytopenia Related to PARP Inhibitors (PancytoRIB)
Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients
All 8 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 8